09/30/2026
Louisiana Attorney General Liz Murrill and the attorneys general in Arkansas and Alabama filed a lawsuit Tuesday in the U.S. Supreme Court, suing California, Massachusetts and New York to invalidate the so-called “shield laws” that have allowed providers in those states to send abortion medication to people in states with abortion bans.
The state officials, all Republicans, also filed a lawsuit in federal district court against individual abortion providers in the same three states.
The lawsuit filed in the Western District of Louisiana seeks to stop the individual providers named from being able to prescribe and send abortion medication to those states, while the Supreme Court complaint asks the justices to find the shield laws are a constitutional violation of state sovereignty..
The complaint compares the mailing of abortion medication to anthrax, mail bombs and chemical weapons, despite studies since 2000 showing that abortion medication is safe and effective to use.
Following the U.S. Supreme Court’s decision in 2022 allowing states to ban abortion at any stage of pregnancy, 13 states now have near-total bans, while others have expanded abortion access.
The U.S. Food and Drug Administration allowed the drug mifepristone, one of two commonly used to terminate a pregnancy in the first trimester or to treat miscarriages, to be dispensed without a visit to an in-person provider in 2023, after years of safety studies.
To protect providers, California, Massachusetts and New York were among the 22 states and the District of Columbia that passed shield laws to block out-of-state investigations and prosecutions against providers dispensing for abortion medications to patients in other states.
Murrill is also leading a lawsuit against the FDA to reverse the 2023 provision allowing telehealth access to mifepristone, and two other lawsuits of a similar nature are ongoing in Missouri and Texas. The 5th U.S. Circuit Court of Appeals heard arguments in Louisiana’s case earlier this month and is expected to issue a decision in the coming weeks about the future of nationwide access to the drug.